---
document_datetime: 2025-11-26 09:18:23
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/obodence-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: obodence-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3066582
conversion_datetime: 2025-12-19 01:08:43.839484
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Obodence

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1 Change in the shelf-life or storage | 26/11/2025                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000312464                     | conditions of the finished product - B.II.f.1.d Change in storage conditions of the finished product or the diluted/reconstituted product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000291542 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted To update sections 5.1, of the SmPC to include the wording regarding study results of glucocorticoid-induced osteoporosis paediatric patients following assessment of the same change for the reference product. Additionally, the MAH takes the opportunity to align the PI with the QRD template, to make minor editorial changes in section 4.2, 4.8 and 5.2 of the SmPC and to update the PI in DE, FR, and HU to correct typographic errors. | 05/09/2025 |     | SmPC | To update sections 5.1, of the SmPC to include the wording regarding study results of glucocorticoid- induced osteoporosis paediatric patients following assessment of the same change for the reference product. Additionally, the MAH takes the opportunity to align the PI with the QRD template, to make minor editorial changes in section 4.2, 4.8 and 5.2 of the SmPC and to update the PI in DE, FR, and HU to correct typographic errors. |
| Variation type IB / EMA/VR/0000278398 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 20/06/2025 | N/A |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                       | testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000276241 | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 05/06/2025 | N/A |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Variation type IB / EMA/VR/0000263754 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.2, 4.4, 4.6, 4.8, 5.1, 6.4, 6.5, and 10 of the SmPC, section 9 of the Labelling, and sections 2, 4, and 5 of the PL to update safety information including a warning regarding hypocalcaemia, reports of life-threatening events and fatal cases occurred in the post marketing setting, a post-marketing observational study (20090522) results, and the information regarding osteonecrosis of | 06/05/2025 |     | SmPC, Labelling and PL | To update sections 4.2, 4.4, 4.6, 4.8, 5.1, 6.4, 6.5, and 10 of the SmPC, section 9 of the Labelling, and sections 2, 4, and 5 of the PL to update safety information including a warning regarding hypocalcaemia, reports of life-threatening events and fatal cases occurred in the post marketing setting, a post-marketing observational study (20090522) results, and the information regarding osteonecrosis of the jaw accordingly following assessment of the same change for the reference product Prolia via procedures EMEA/H/C/001120/II/0099 and EMEA/H/C/001120/II/0100. |

<div style=\"page-break-after: always\"></div>

| the same change for the reference product Prolia via procedures EMEA/H/C/001120/II/0099 and EMEA/H/C/001120/II/0100. In addition, the MAH has taken the opportunity to introduce editorial corrections in all languages to align with the QRD guideline, to make an editorial correction in Italian language to align with the reference product PI, to correct an image in the German PI (section IIIB), and to correct typographic errors in the Bulgarian PI.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|